Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma

Clin Lung Cancer. 2022 Mar;23(2):e137-e139. doi: 10.1016/j.cllc.2021.07.007. Epub 2021 Jul 19.

Authors

Ranjan Pathak¹, Ravi Salgia²

Affiliations

¹ Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA. Electronic address: rpathak@coh.org.
² Department of Medical Oncology and Therapeutics Research, City of Hope, Duarte, CA.

PMID: 34419376
DOI: 10.1016/j.cllc.2021.07.007

No abstract available

Keywords: Chemoimmunotherapy; Immunotherapy; KRAS; Lung cancer; STK11; biomarkers.

Publication types

Case Reports

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Antibodies, Monoclonal, Humanized / therapeutic use*
Biomarkers, Tumor
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Male
Mutation
Neoplasm Staging
Platinum / therapeutic use*
Proto-Oncogene Proteins p21(ras) / metabolism*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Biomarkers, Tumor
KRAS protein, human
Platinum
pembrolizumab
Proto-Oncogene Proteins p21(ras)